DXB Shares Dimerix Limited
ACCUMULATE ASX · ASXPhase 3 kidney-disease program offers a near-term clinical and commercial catalyst.
Future value: $0.32 (+60.00%) · 6-12 months
Signal breakdown
- ▸Phase 3 treatment milestone and ongoing clinical development.
- ▾Below 50-day MA (-19.45%)
- ▾Near 52-week low (8.4% of range)
- ▸~60% upside to price target
Is DXB a buy right now?
Trend: DXB is trading below the 50-day average (-20.00%), RSI 37 — neutral momentum, with a 3-month return of -20.00%.
Valuation & quality: Dimerix Limited trades on forward P/E -10.0, PEG 0.72; fundamentals show net margin 0.0%, revenue growth -20.0% year on year.
Analyst consensus: 1 analysts have a mean 12-month price target of A$1.90 (+847.5% vs the last close; range A$1.90 – A$1.90), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Phase 3 kidney-disease program offers a near-term clinical and commercial catalyst.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -34.00% | -25.80% | -17.40% | +5.30% | +25.00% | +12.00% | -17.90% | -13.00% |
Fundamentals
Analyst price target
Technical signals
About Dimerix Limited
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury.
Sector: Healthcare · Industry: Biotechnology · Australia · 15 employees · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.